Japan's Takeda Pharmaceutical has completed enrollment for a 20,000-subject phase 3 dengue vaccine trial, the largest clinical study in its history.
The global study will test the experimental vaccine on 20,100 children and adolescents in eight countries in Latin America and Asia where the mosquito-borne disease is endemic.
The vaccine could potentially rival Sanofi Pasteur's Dengvaxia, which did not prove to protect equally against the four different serotypes of dengue.
Takeda is pushing to become more global with its vaccines business under the leadership of CEO Christophe Weber. Last November, Takeda announced it planned to invest more than $107 million to build a new manufacturing plant in Germany for its dengue vaccine candidate.
Read the CNBC article
